Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study.

ABSTRACT:

Background

Treatment strategy against immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) frequently requires other immunosuppressive agents. Tofacitinib is a rapidly acting JAK-STAT inhibitor with proven efficacy in multiple autoimmune diseases. We aimed to evaluate the efficacy and safety of tofacitinib in the management of irAEs in cancer patients.

Methods

Cancer patients who received ICIs and were treated with tofacitinib for the management of irAEs at 6 institutions were retrospectively included in this study. Demographic and clinical characteristics were obtained from electronic medical records. Longitudinal assessment of cardiac troponin T (cTnT) with clinical assessment was utilized to evaluate the benefit of tofacitinib treatment in

SUBMITTER: Liu Q 

PROVIDER: S-EPMC11360683 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature